144 0001103804 XXXXXXXX LIVE 0001743881 BridgeBio Pharma, Inc. 001-38959 3160 Porter Drive Suite 250 Palo Alto CA 94304 (650) 391-9740 VIKING GLOBAL INVESTORS LP 10% Stockholder Common Stock Citigroup

388 Greenwich Street New York NY 10013

3065616 106989998.4 188989802 01/31/2025 NASDAQ Common Stock 06/27/2019 Purchases in Issuer's IPO Underwriter N 625937 07/01/2019 Cash Common Stock 06/27/2019 Conversion of Series C Preferred Units in Issuer's IPO Issuer N 479280 08/15/2017 Cash Common Stock 06/27/2019 Conversion of Series C Preferred Units in Issuer's IPO Issuer N 479280 12/15/2017 Cash Common Stock 06/27/2019 Conversion of Series C Preferred Units in Issuer's IPO Issuer N 347956 04/10/2018 Cash Common Stock 06/27/2019 Conversion of Series D Preferred Units in Issuer's IPO Issuer N 1133163 11/20/2018 Cash Y The shares reported herein were sold by the following funds managed by the reporting person: Viking Global Opportunities Illiquid Investments Sub-Master LP, Viking Global Equities Master Ltd. and Viking Long Fund Master Ltd. 01/31/2025 /s/ Scott M. Hendler, Authorized Signatory